| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2771757 | Seminars in Arthritis and Rheumatism | 2010 | 14 Pages |
Abstract
The increasing use of biologic agents for treatment of rheumatic diseases has raised important questions about cost, safety, and effectiveness of these agents. The unique and variable features of patient populations and registry designs in Europe and the U.S. provide valuable and complementary data on comparative effectiveness and safety of biologic agents to what can be derived from RCTs.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jeffrey R. MD, MS, MPH, Archana MD, Johan MD, PhD, S. Louis MD, PhD, Loreto MD, PhD, William MRCP, PhD, Axel MD, MS, Kimme MD, PhD, FRCPC, Jeffrey D. MD, MPH, Joel MD, Joachim PhD, Kaleb PhD, Ted MD, MSPH, Nancy MD, MPH, Daniel H. MD, MPH, Michael E. MD,